1. Home
  2. INCY vs LSCC Comparison

INCY vs LSCC Comparison

Compare INCY & LSCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

SELL

Current Price

$111.48

Market Cap

17.0B

Sector

Health Care

ML Signal

SELL

Logo Lattice Semiconductor Corporation

LSCC

Lattice Semiconductor Corporation

SELL

Current Price

$122.85

Market Cap

17.2B

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
INCY
LSCC
Founded
1991
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
17.2B
IPO Year
1994
1994

Fundamental Metrics

Financial Performance
Metric
INCY
LSCC
Price
$111.48
$122.85
Analyst Decision
Buy
Strong Buy
Analyst Count
28
14
Target Price
$129.13
★ $164.21
AVG Volume (30 Days)
1.6M
★ 1.8M
Earning Date
10-29-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 4173.33
N/A
EPS
★ 1.47
0.29
Revenue
★ $3,394,635,000.00
$385,961,000.00
Revenue This Year
$15.49
$75.77
Revenue Next Year
$5.35
$45.13
P/E Ratio
★ $76.76
$432.50
Revenue Growth
★ 13.67
N/A
52 Week Low
$83.50
$60.50
52 Week High
$132.60
$157.01

Technical Indicators

Market Signals
Indicator
INCY
LSCC
Relative Strength Index (RSI) 29.48 48.50
Support Level $110.56 $111.89
Resistance Level $119.29 $126.35
Average True Range (ATR) 3.13 4.31
MACD -1.15 0.01
Stochastic Oscillator 7.20 28.26

Price Performance

Historical Comparison
INCY
LSCC

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About LSCC Lattice Semiconductor Corporation

Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.

Share on Social Networks: